ClosedResearch2025 Clinical Trials Activity

MRFF – CTA Initiative – 2025 Clinical Trials Activity Grant Opportunity

National Health and Medical Research Council (NHMRC) · Australia

This Medical Research Future Fund grant supports clinical trial research and medical innovation projects across four streams, including pilot studies, targeted clinical trials, health technology assessment evidence generation, and prevention trials. It aims to improve access to high-quality, evidence-based and effective health care for Australians.

Funding

Up to $5M

Closed

1 Apr 2026

Duration

within 7 years of execution of the grant schedule

Location

Australia

Who Can Apply

Approved MRFF Eligible Organisations only Research must address one of the four specified streams Applications must meet all requirements in the grant opportunity guidelines Applications are submitted electronically through NHMRC's Sapphire system
Applications will only be accepted from approved MRFF Eligible Organisations listed on the NHMRC MRFF Eligible Organisations List. Applications must satisfy all requirements set out in the Medical Research Future Fund – Clinical Trials Activity Initiative - 2025 Clinical Trials Activity Grant Opportunity Guidelines. Applicants must propose research that addresses one of the four specified research streams.

What's Funded

Conducting pilot studies and clinical trials for rare cancers, rare diseases, unmet needs, health technology assessment evidence gaps, and disease prevention through early intervention strategies.

Expected Outcomes

Improved evidence supporting clinical care, increased patient access to relevant trials, support for bringing international trials to Australian patients, and improved health and wellbeing of Australians through high-quality evidence-based care.

Key Information

Applicant Types

universityother

Stage

any

Funding Purposes

researchinnovation

Keywords

MRFFclinical trialsmedical researchmedical innovationrare cancerrare diseaseunmet needprevention

Frequently Asked Questions

What is the MRFF – CTA Initiative – 2025 Clinical Trials Activity Grant Opportunity?

The MRFF – CTA Initiative – 2025 Clinical Trials Activity Grant Opportunity is a research grant offered by National Health and Medical Research Council (NHMRC) in Australia, providing Up to $5M in funding. This Medical Research Future Fund grant supports clinical trial research and medical innovation projects across four streams, including pilot studies, targeted clinical trials, health technology assessment evidence generation, and prevention trials. It aims to improve access to high-quality, evidence-based and effective health care for Australians.

How much funding does the MRFF – CTA Initiative – 2025 Clinical Trials Activity Grant Opportunity provide?

The MRFF – CTA Initiative – 2025 Clinical Trials Activity Grant Opportunity provides Up to $5M in funding. The typical project duration is within 7 years of execution of the grant schedule.

Who is eligible for the MRFF – CTA Initiative – 2025 Clinical Trials Activity Grant Opportunity?

Approved MRFF Eligible Organisations only Research must address one of the four specified streams Applications must meet all requirements in the grant opportunity guidelines Applications are submitted electronically through NHMRC's Sapphire system

When does the MRFF – CTA Initiative – 2025 Clinical Trials Activity Grant Opportunity close?

Applications closed on 1 Apr 2026.

What activities are funded?

Conducting pilot studies and clinical trials for rare cancers, rare diseases, unmet needs, health technology assessment evidence gaps, and disease prevention through early intervention strategies.

How do I apply for the MRFF – CTA Initiative – 2025 Clinical Trials Activity Grant Opportunity?

Start by checking your eligibility using the free Beta Docs eligibility checker. If eligible, Beta Docs' AI-powered platform can help you draft, review, and refine your application to maximise your chances of success.

Need help applying?

Beta Docs has helped founders secure $160M+ in competitive grants. Our AI platform drafts compliance-perfect applications — and our expert reviewers make sure you stand out.